- Home
- BRBI vs CLLS Comparison
BRBI vs CLLS Comparison
Compare BRBI & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BRBI | CLLS |
|---|---|---|
| Founded | 2009 | 1999 |
| Country | Brazil | France |
| Employees | 188 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 383.0M | 394.4M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | BRBI | CLLS |
|---|---|---|
| Price | $12.77 | $3.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.33 |
| AVG Volume (30 Days) | 1.1K | ★ 19.4K |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | ★ 5.03% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $17.24 | $0.98 |
| P/E Ratio | $11.72 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.54 | $1.33 |
| 52 Week High | $67.01 | $5.48 |
Technical Indicators
Market Signals| Indicator | BRBI | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 31.70 | 42.24 |
| Support Level | $12.76 | $3.40 |
| Resistance Level | $15.06 | $3.83 |
| Average True Range (ATR) | 0.20 | 0.21 |
| MACD | -0.15 | -0.04 |
| Stochastic Oscillator | 0.00 | 14.86 |
Price Performance
Historical ComparisonAbout BRBI BRBI BR Partners S.A. ADSs
BRBI BR Partners SA, formerly BR Advisory Partners Participacoes SA, is engaged in investing in other companies, domestic or foreign, as a partner, quota holder, or shareholder, and management of its assets. It has a single reportable segment being investment banking services, which are administered and managed according to the products offered.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.